I3IN-002

• Description:

  I3IN-002 is a small-molecule RNA-binding protein IGF2BP3 inhibitor with an IC50 value of approximately 2 μM in SEM cells. I3IN-002 interferes with interaction with m6 A-modified mRNAs, disrupting the stabilization of target genes (such as CDK6, MYC, and BCL2) to inhibit leukemic cell growth, induce cell cycle arrest, and promote apoptosis. I3IN-002 is promising for research of B-cell acute lymphoblastic leukemia[1][2].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Insulin Receptor

• Related Pathways:

  Apoptosis; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.35

• Solubility:

  DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(NC1=C(C(F)(F)F)C=CC=C1)CSC(N=N2)=NC3=C2C4=CC(CC)=CC=C4N3

• Molecular Formula:

  C20H16F3N5OS

• Molecular Weight:

  431.43

• References & Citations:

  [1]Jaiswal A K, et al. A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity[J]. bioRxiv, 2025: 2025.04. 14.648780.|[2]Sharma G, et al. Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3. bioRxiv [Preprint]. 2024 Nov 3:2024.10.31.621399.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [552829-57-9]